Leveraging the holistic benefits of biosimilars in Europe–part 2: how payers can safeguard the future of a healthy biosimilar market environment
J Mestre-Ferrandiz, M Czech, JS Smolen… - Expert Review of …, 2024 - Taylor & Francis
Introduction Biosimilars have improved access to biologic medicines; however, historical
thinking may jeopardize the viability of future markets. Areas covered An expert panel of …
thinking may jeopardize the viability of future markets. Areas covered An expert panel of …
Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review
NM Bressler, PK Kaiser, DV Do, QD Nguyen… - Survey of …, 2024 - Elsevier
The development of intravitreally injected biologic medicines (biologics) acting against
vascular endothelial growth factor (VEGF) substantially improved the clinical outcomes of …
vascular endothelial growth factor (VEGF) substantially improved the clinical outcomes of …
[HTML][HTML] Biosimilar Medicines: From Development Process to Marketing Authorization by the EMA and the FDA
Biosimilars are a new category of medicines that have revolutionized the treatment of
patients with life-threatening conditions, such as cancer and autoimmune diseases. A …
patients with life-threatening conditions, such as cancer and autoimmune diseases. A …
[HTML][HTML] Biosimilars in the Era of Artificial Intelligence—International Regulations and the Use in Oncological Treatments
This research is based on three fundamental aspects of successful biosimilar development
in the challenging biopharmaceutical market. First, biosimilar regulations in eight selected …
in the challenging biopharmaceutical market. First, biosimilar regulations in eight selected …
Deciphering the US Regulatory Framework: Comparison Between Oncology Biosimilars and Reference Biologics
A Tandulje, P Varpe, P Chaugule, RS Raghuvanshi… - Seminars in …, 2024 - Elsevier
Biological oncology agents are vital in cancer care, but their exorbitant expenses present
obstacles for patients, families, healthcare professionals, and insurance providers. The …
obstacles for patients, families, healthcare professionals, and insurance providers. The …
Research and pilot analysis of bevacizumab repurposing potential and its impact in clinical practice
A Ivanov, V Getova-Kolarova, V Belcheva… - Biotechnology & …, 2024 - Taylor & Francis
Repurposing of drugs is a strategy for discovering new uses for already authorized or tested
medicines outside their original indications. Bevacizumab is humanized antibody, observed …
medicines outside their original indications. Bevacizumab is humanized antibody, observed …
Optimising oncology drug expenditure in Ireland
R Kieran, M Hennessy, K Coakley, H O'Sullivan… - Irish Journal of Medical …, 2024 - Springer
A combination of improvements in patient survival, increasing treatment duration, and the
development of more expensive agents has led to a doubling of per-capita spending on …
development of more expensive agents has led to a doubling of per-capita spending on …
Provider perceptions of barriers to biosimilar utilization in community oncology practices
O Briggs, CM Brown, P Indurlal, JS Garey… - Journal of the American …, 2024 - Elsevier
Background Biosimilars reduce the burden of cost on patients and payers, and so doing,
increase access to life-saving care. However, biosimilar uptake in the US has been …
increase access to life-saving care. However, biosimilar uptake in the US has been …
Regulatory Considerations of Biosimilars in Cancer
L Nagar, A Saini, N Gulati, N Solanki… - Biosimilars for Cancer …, 2024 - Springer
In the fast-evolving field of cancer treatment, the introduction of biosimilars has brought
about significant changes in the available therapeutic options. Biosimilars, which are …
about significant changes in the available therapeutic options. Biosimilars, which are …
[HTML][HTML] Quantification of the Cellular Content of Platelet Rich Plasma Harvested After Injection of Filgrastim Versus Pegfilgrastim Biosimilars: A Prospective, Single …
M Abbasian, E Branch, A Parsa, J Truett… - Journal of Cartilage & …, 2024 - Elsevier
Abstract Background Hematopoietic stem cells (HSCs) are primitive cells that often appear
in peripheral blood (PB) following mobilization events from bone marrow due to stress …
in peripheral blood (PB) following mobilization events from bone marrow due to stress …